Vor to Develop Multi-Targeted CAR-Ts with Abound Bio
10 juin 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license...
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
25 mai 2021 16h10 HE
|
Vor Biopharma
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...
Vor Reports First Quarter 2021 Financial Results and Provides Company Update
06 mai 2021 16h08 HE
|
Vor Biopharma
Health Canada clears the CTA for VOR33 clinical trial Vor to present on VOR33 manufacturing scale-up and in-depth genomic characterization at the American Society of Gene & Cell Therapy (ASGCT)...
Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
28 avr. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) is pleased to announce that Vor scientists will give two presentations documenting the development, manufacturing,...
Vor Reports Fiscal Year 2020 Financial Results
25 mars 2021 16h35 HE
|
Vor Biopharma
IND accepted for VOR33, Vor’s lead eHSC product candidate for treatment of AML Completed initial public offering raising $203.4 million in total gross proceeds CAMBRIDGE, Mass.,...
Vor Biopharma to Present at the Barclays Global Healthcare Conference
05 mars 2021 15h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
01 mars 2021 15h45 HE
|
Vor Biopharma
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
09 févr. 2021 16h05 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Announces Pricing of Initial Public Offering
05 févr. 2021 06h33 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...